PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED
Study Details
Study Description
Brief Summary
The goal of this research is to increase COVID-19 and influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients). Toward this goal, the investigators will conduct one on one interviews and focus groups with ED Usual Source of Care Patients and community partners and produce trusted messaging informational platforms (PROmotion of COvid-19 VA(X)ccination in the Emergency Department - PROCOVAXED) that will address barriers to COVID-19 and influenza vaccination, especially vaccine hesitancy. The investigators will then conduct a cluster-randomized, controlled trial of PROCOVAXED platforms in six EDs to determine whether their implementation is associated with greater COVID-19 and influenza vaccine acceptance and uptake in ED Usual Source of Care Patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The investigator's preliminary work research at 15 ED sites across the US indicates that ED Usual Source of Care patients have particular health care access barriers, needs, and perceptions about vaccines (vaccine hesitancy) that require specific review beyond traditional (non-ED user) community engagement techniques. To gain insight about messaging that effectively addresses these barriers, needs, and perceptions, the investigators will conduct one on one interviews and focus group meetings with ED Usual Source of Care Patients and community partners.
At five safety net EDs (Zuckerberg San Francisco General, Thomas Jefferson University Hospital [Philadelphia], Methodist Hospital [Philadelphia], Harborview Medical Center [Seattle], and Duke University Medical Center [Durham, NC], the investigators will conduct a cluster-randomized, controlled trial of implementation of PROCOVAXED platforms, with COVID-19 and influenza vaccine acceptance rates on post-intervention ED surveys as the primary outcomes. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with increased acceptance of COVID-19 and influenza vaccines in ED patients.
One month after subjects' index ED visit enrollment in our PROCOVAXED implementation trial, the investigators will conduct electronic health record review and phone follow-up surveys to determine ED patient uptake (receipt) of COVID-19 and influenza vaccines. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with greater COVID-19 and influenza vaccine uptake in ED patients.
The investigators will conduct a cluster-randomized, controlled trial (RCT) of implementation of our PROCOVAXED platforms in 5 high-volume, safety net hospital EDs, testing two hypotheses that implementation of PROCOVAXED platforms will be associated with increased acceptance and uptake of COVID-19 and influenza vaccines in ED Usual Source of Care Patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention Arm Covid vaccine educational intervention consisting of vaccine messaging platforms (flyers, videos, scripted face-to-face messaging) |
Other: Covid-19 vaccine education materials
videos and flyers containing Covid-19 vaccine educational information
|
| No Intervention: Non-interventional Arm Usual care |
Outcome Measures
Primary Outcome Measures
- Covid-19 vaccine acceptance in the emergency department [Within 6 hours of intervention]
Participant acceptance of the COVID-19 vaccine assessed by the question "Would you accept the COVID-19 vaccine in the emergency department today if your doctor or provider asked you to get it?" The response choices for this question are "Yes", "No", and "No, but I might consider getting it at some other time". This question will be asked once at the end of the Emergency Department visit.
- Covid-19 vaccine uptake [Within 32 days of intervention]
Participation uptake of the COVID-19 vaccine 32 days after enrollment assessed by confirmation of receipt of vaccine in one of 3 ways: Receipt in emergency department during index (enrollment) visit Electronic health record review 30 days after index visit Follow up phone call to participant at 28 to 32 days - We are asking patients if they received a COVID-19 vaccine since their index emergency department visit.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Adults (>18 years of age) patients who are receiving care at participating Emergency Departments and have not yet received a COVID-19 vaccine
Exclusion Criteria:
-
major trauma patients
-
patients transferred from another hospital, chronic care facility, nursing home or hospice,
-
patients unable to participate in an interview because of intoxication, altered mental status or critical illness
-
incarcerated patients
-
patients on psychiatric holds
-
patients who have received a COVID-19 vaccine
-
under suspicion for acute COVID-19 illness
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | San Francisco General Hospital Emergency Department | San Francisco | California | United States | 94110 |
| 2 | University of California, San Francisco - Parnassus | San Francisco | California | United States | 94143 |
| 3 | Duke University Hospital | Durham | North Carolina | United States | 27708 |
| 4 | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | United States | 19107 |
| 5 | Jefferson Torresdale Hospital | Philadelphia | Pennsylvania | United States | 19114 |
| 6 | Jefferson Methodist Hospital | Philadelphia | Pennsylvania | United States | 19148 |
| 7 | University of Washington-Harborview Emergency Department | Seattle | Washington | United States | 98104 |
Sponsors and Collaborators
- University of California, San Francisco
- Duke University
- Thomas Jefferson University
- University of Washington
Investigators
- Principal Investigator: Robert Rodriguez, MD, University of California, San Francisco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21-34004